bristol myers-squibb

Showing 6 posts of 6 posts found.


“Underwhelming” drug data devastates Nektar, shares fall by 42%

June 5, 2018
Manufacturing and Production, Research and Development ASCO, BMS, Bristol-Myers Squibb, Cancer, Nektar, bristol myers-squibb, pharma

Nektar Therapeutics has seen its share price devastated after revealing disappointing trial data for its candidate NKTR-214 in combination with …


New formulary ‘bank’ to aid research into combination therapies

January 11, 2017
Medical Communications, Research and Development 21st Century Cures Act, Bristol-Myers Squibb, Eli Lilly, Joe Biden, Obama, bristol myers-squibb, combination therapy

As part of the wider ‘cancer moonshot’ initiative, confirmed by the signing of the 21st Century Cures Act by Obama, …


Giovanni Caforio to be made chairman of the board at BMS

January 3, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, Giovanni Caforio, bristol myers-squibb

Bristol-Myers Squibb has announced that Giovanni Caforio has been appointed chairman of the board. Caforio will take up the position …


Opdivo first PD-1 inhibitor given European approval for haematological cancer

November 25, 2016
Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, EMA, PD1-Inhibitor, bristol myers-squibb

Bristol-Myers Squibb announced that it has received the first and only European approval for a PD1 inhibitor in the treatment …

BMS image

BMS lung cancer drug scores in Phase II

October 31, 2014
Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, FDA, NSCLC, bristol myers-squibb, odivo

Bristol-Myers Squibb is still in the hunt to gain significant market share in the PD-1 therapeutic vaccine race after releasing …

BMS image

BMS therapeutic cancer vaccine given swift FDA appraisal

September 29, 2014
Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, FDA, Vaccine, bristol myers-squibb, keytruda, melanoma, opdivo

Bristol-Myers Squibb has been granted a speedy review for its new cancer immunotherapy drug Opdivo by the FDA for patients …

Latest content